Adenocarcinoma of the lung pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{Trusha}}, {{SC}}, {{Cherry}}
{{CMG}}; {{AE}} {{Trusha}}, {{SC}}, {{Cherry}}
==Overview==
==Overview==
Adenocarcinoma is the most common type of lung cancer found in non-smokers and is usually seen as a peripheral lesion in the [[Lung|lungs]]. In past several years many genetic and environmental factors hace been identified as a causative factor for lunng cancer. Individual susceptibility, active [[smoking]], [[radon]] exposure, exposure to high pollution levels, [[asbestos]] exposure, occupational or environmental exposure to particular agents or [[Carcinogen|carcinogens]] contribute to the development of adenocarcinoma of the lung. [[Hydrocarbon|Hydrocarbons]] cause damage to the [[DNA]] and form DNA adducts. Benzo-A-pyrine has effects on inducing [[P53 (protein)|p53]] mutations and affects [[Signaling pathway|molecular signaling pathways]] such as [[AKT]]. [[Gene|Genes]] involved in the pathogenesis of adenocarcinoma of the lung include [[epidermal growth factor receptor|EGFR]], [[HER2]], [[KRAS]], [[anaplastic lymphoma kinase|ALK]], and [[BRAF]]. On gross pathology, peripheral multifocal lesions are characteristic findings in [[Patient|patients]] with adenocarcinoma of the lung. On microscopic histopathological analysis, nuclear atypia, eccentrically placed [[Cell nucleus|nuclei]], abundant [[cytoplasm]], and conspicuous [[Nucleolus|nucleoli]] are characteristic findings of adenocarcinoma of the lung.
Adenocarcinoma is the most common type of lung cancer found in non-smokers and is usually seen as a peripheral lesion in the [[Lung|lungs]]. In past several years many genetic and environmental factors has been identified as a causative factor for lung cancer. Individual susceptibility, active [[smoking]], [[radon]] exposure, exposure to high pollution levels, [[asbestos]] exposure, occupational or environmental exposure to particular agents or [[Carcinogen|carcinogens]] contribute to the development of adenocarcinoma of the lung. [[Hydrocarbon|Hydrocarbons]] cause damage to the [[DNA]] and form DNA adducts. Benzo-A-pyrine has effects on inducing [[P53 (protein)|p53]] mutations and affects [[Signaling pathway|molecular signaling pathways]] such as [[AKT]]. [[Gene|Genes]] involved in the pathogenesis of adenocarcinoma of the lung include [[epidermal growth factor receptor|EGFR]], [[HER2]], [[KRAS]], [[anaplastic lymphoma kinase|ALK]], and [[BRAF]]. On gross pathology, peripheral multifocal lesions are characteristic findings in [[Patient|patients]] with adenocarcinoma of the lung. On microscopic histopathological analysis, nuclear atypia, eccentrically placed [[Cell nucleus|nuclei]], abundant [[cytoplasm]], and conspicuous [[Nucleolus|nucleoli]] are characteristic findings of adenocarcinoma of the lung.


==Pathogenesis==
==Pathogenesis==
* Adenocarcinoma is the most common type of lung cancer found in non-smokers and is usually seen as a peripheral lesion in the [[Lung|lungs]], as compared to centrally located tumors such as [[small cell lung cancer]] and [[squamous cell]] lung cancer.<ref name="Travis95">{{cite journal |author=Travis WD, Travis LB, Devesa SS |title=Lung cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=191–202 |date=January 1995|pmid=8000996 |doi= 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y|url=}}</ref><ref name="Kumar-adenocarcinoma">{{cite book |chapter=Chapter 13, box on morphology of adenocarcinoma |author=Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson |title=Robbins Basic Pathology|publisher=Saunders |location=Philadelphia |isbn=1-4160-2973-7 |edition=8th}}</ref>
* Adenocarcinoma is the most common type of [[lung cancer]] found in non-smokers and is usually seen as a peripheral lesion in the [[Lung|lungs]], as compared to centrally located tumors such as [[small cell lung cancer]] and [[squamous cell]] lung cancer.<ref name="Travis95">{{cite journal |author=Travis WD, Travis LB, Devesa SS |title=Lung cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=191–202 |date=January 1995|pmid=8000996 |doi= 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y|url=}}</ref><ref name="Kumar-adenocarcinoma">{{cite book |chapter=Chapter 13, box on morphology of adenocarcinoma |author=Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson |title=Robbins Basic Pathology|publisher=Saunders |location=Philadelphia |isbn=1-4160-2973-7 |edition=8th}}</ref>
* Lung cancer [[pathogenesis]] can be understood with the help of following [[hypothesis]].<ref name="KanwalDing2017">{{cite journal|last1=Kanwal|first1=Madiha|last2=Ding|first2=Xiao-Ji|last3=Cao|first3=Yi|title=Familial risk for lung cancer|journal=Oncology Letters|volume=13|issue=2|year=2017|pages=535–542|issn=1792-1074|doi=10.3892/ol.2016.5518}}</ref><ref name="KadaraScheet2016">{{cite journal|last1=Kadara|first1=H.|last2=Scheet|first2=P.|last3=Wistuba|first3=I. I.|last4=Spira|first4=A. E.|title=Early Events in the Molecular Pathogenesis of Lung Cancer|journal=Cancer Prevention Research|volume=9|issue=7|year=2016|pages=518–527|issn=1940-6207|doi=10.1158/1940-6207.CAPR-15-0400}}</ref><ref name="RasoWistuba2007">{{cite journal|last1=Raso|first1=Maria Gabriela|last2=Wistuba|first2=Ignacio I.|title=Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers|journal=Journal of Thoracic Oncology|volume=2|issue=7|year=2007|pages=S128–S135|issn=15560864|doi=10.1097/JTO.0b013e318074fe42}}</ref>
* '''Familial lung cancer''':
** [[Chromosome 6 (human)|6q23–25]] [[Locus (genetics)|locus]] has been identified as a [[Susceptible individual|susceptibility]] [[gene]] for familial lung cancer.
 
* '''Multistep tumorigenesis''':
** [[Tumor|Tumors]] of organs such as [[Skin cancer|skin]], [[lung]] and [[Colorectal cancer|colon]] are developed through a process called [[Tumorigenesis|multistep tumorigenesis]].<ref name="pmid18039118">{{cite journal |vauthors=Wistuba II, Gazdar AF |title=Lung cancer preneoplasia |journal=Annu Rev Pathol |volume=1 |issue= |pages=331–48 |date=2006 |pmid=18039118 |doi=10.1146/annurev.pathol.1.110304.100103 |url=}}</ref>
** As with other epithelial malignancies, lung cancers are believed to arise from preneoplastic or precursor lesions in the respiratory mucosa.
** [[Tumorigenesis|Multistep tumorigenesis]] is development of [[tumor]] through a series of progressive pathologic events such as [[Precancerous|preneoplastic]] or [[Precursor|precursor lesions]] with corresponding [[genetic]] and [[Epigenetic|epigenetic aberrations]].
** [[Hyperplasia]], [[squamous metaplasia]], [[Dysplasia|squamous dysplasia]], and [[Carcinoma in situ|carcinoma ''in situ'' (CIS)]] comprise changes in the [[Bronchus|large airways]] that precede or accompany invasive [[squamous cell carcinoma of the lung]].
** Multistep tumorigenesis explains pathogenesis of centrally located squamous cell carcinoma of the lung very well but fails to explain pathogenesis of [[Large cell carcinoma of the lung|large cell lung carcinomas]], [[Adenocarcinoma of the lung|lung adenocarcinomas]], and [[small cell lung cancer]].
 
* '''Accumulation of molecular abnormalities:'''
** Another theory for pathogenesis of lung cancer is the accumulation of molecular abnormalities beyond a certain threshold point, rather than the sequence of alterations.
** There are no known [[Precancerous|preneoplastic lesions]] for the most common type of [[Carcinoid syndrome|neuroendocrine lung tumors]], [[Small cell lung cancer|small cell carcinoma of the lung]],
** Atypical adenomatous hyperplasia (AAH) is the only sequence of morphologic change identified leading to the development of [[Adenocarcinoma of the lung|invasive adenocarcinoma of the lung.]]
* [[Pathogenesis]] of lung cancer is thought to be result of both due to stepwise, sequence-specific and multistage [[Molecular pathology|molecular pathogenesis]] and due to accumulation and combination of [[Genetics|genetic]] and [[Epigenetics|epigenetic]]<nowiki/>abnormalities.
 
=== Field of injury and field cancerization ===
* [[Premalignant condition|Preneoplastic lung lesions]] frequently extend throughout the [[respiratory epithelium]], indicating a field effect in which much of the [[respiratory epithelium]] has been [[Mutagen|mutagenized]], presumably from exposure to tobacco-related carcinogens.<ref name="DevarakondaMorgensztern2015">{{cite journal|last1=Devarakonda|first1=Siddhartha|last2=Morgensztern|first2=Daniel|last3=Govindan|first3=Ramaswamy|title=Genomic alterations in lung adenocarcinoma|journal=The Lancet Oncology|volume=16|issue=7|year=2015|pages=e342–e351|issn=14702045|doi=10.1016/S1470-2045(15)00077-7}}</ref><ref name="pmid27006378">{{cite journal |vauthors=Kadara H, Scheet P, Wistuba II, Spira AE |title=Early Events in the Molecular Pathogenesis of Lung Cancer |journal=Cancer Prev Res (Phila) |volume=9 |issue=7 |pages=518–27 |date=July 2016 |pmid=27006378 |doi=10.1158/1940-6207.CAPR-15-0400 |url=}}</ref><ref name="AuerbachStout1961">{{cite journal|last1=Auerbach|first1=Oscar|last2=Stout|first2=A. P.|last3=Hammond|first3=E. Cuyler|last4=Garfinkel|first4=Lawrence|title=Changes in Bronchial Epithelium in Relation to Cigarette Smoking and in Relation to Lung Cancer|journal=New England Journal of Medicine|volume=265|issue=6|year=1961|pages=253–267|issn=0028-4793|doi=10.1056/NEJM196108102650601}}</ref>
* [[Epithelium|Epithelial cells]] lining the entire [[respiratory tract]] that have been exposed to [[smoking]] show [[Molecular pathology|molecular alterations]] that may signify the onset of lung cancers, a [[paradigm]] known as the "airway field of injury”.
* [[Premalignant]] [[airway]] fields in the molecular pathogenesis of lung cancer:
** [[Smoking]] induces widespread [[Molecular pathology|molecular alterations]], such as [[gene expression]] changes in exposed [[Epithelium|epithelia]] throughout the [[Respiratory tract|respiratory tract.]]
** The [[airway]] field of injury can be seen in smokers with or without lung cancer and is highly relevant for the identification of [[Tumor marker|markers]] for [[Minimally invasive adenocarcinoma of the lung|minimally invasive]] and early detection of lung cancer.
** The adjacent [[airway]] field of [[Oncogenesis|carcinoma]] represents the field in normal appearing [[Airway|airways]] adjacent to [[lung]] [[Tumor|tumors]].
** It has been suggested that in this adjacent field of [[tumor]], there is closer [[Molecular pathology|molecular genealogy]] between lung cancers and [[Airway|airways]] that are in closest proximity to the [[Tumor|tumors]] compared with [[Airway|airways]] that are more distant from the [[tumors]].
** The progression of the molecular airway field of injury to [[Precancerous|preneoplasia]] and lung malignancy is still not clear.
** [[Molecular pathology|Molecular changes]] involved in the development of the [[airway]] field of injury and changes mediating progression of this field to [[lung]] [[Precancerous|preneoplasia]] may help the identification of early [[Marker|markers]] for lung cancer detection and [[Chemoprophylaxis|chemoprevention]].
 
*
*
*


*Individual susceptibility, active [[smoking]], [[radon]] exposure, exposure to high pollution levels, [[asbestos]] exposure, occupational or environmental exposure to particular agents or [[Carcinogen|carcinogens]] contribute to the development of adenocarcinoma of the [[lung]]. [[Hydrocarbon|Hydrocarbons]] cause damage to the [[DNA]] and form DNA adducts. Benzo-A-pyrine has effects on inducing [[P53 (protein)|p53]] mutations and affects [[Signaling pathway|molecular signaling pathways]] such as [[AKT]].  
*Individual susceptibility, active [[smoking]], [[radon]] exposure, exposure to high pollution levels, [[asbestos]] exposure, occupational or environmental exposure to particular agents or [[Carcinogen|carcinogens]] contribute to the development of adenocarcinoma of the [[lung]]. [[Hydrocarbon|Hydrocarbons]] cause damage to the [[DNA]] and form DNA adducts. Benzo-A-pyrine has effects on inducing [[P53 (protein)|p53]] mutations and affects [[Signaling pathway|molecular signaling pathways]] such as [[AKT]].  
*A locus on chromosome 6q23–25 has been reported as conferring lung cancer susceptibility among families with multiple members affected by lung or head and neck cancer.
*The “multiple hit theory” for adenocarcinoma of the [[lung]] states that genetic [[reproduction]] is hindered due to the cumulative effect of several toxic insults. Underlying [[lung]] disease such as [[Chronic obstructive pulmonary disease|COPD]], [[idiopathic pulmonary fibrosis]] and [[tuberculosis]] may exacerbate also trigger the process.
*The “multiple hit theory” for adenocarcinoma of the [[lung]] states that genetic [[reproduction]] is hindered due to the cumulative effect of several toxic insults. Underlying [[lung]] disease such as [[Chronic obstructive pulmonary disease|COPD]], [[idiopathic pulmonary fibrosis]] and [[tuberculosis]] may exacerbate also trigger the process.
*Mutations involving several [[Oncogene|oncogenes]] may lead to the development of adenocarcinoma of the lung. These are as follows:
*Mutations involving several [[Oncogene|oncogenes]] may lead to the development of adenocarcinoma of the lung. These are as follows:
**Mutations of [[ras]] (found in thirty percent of cases) affect [[signal transduction]] by affecting [[GTPase]] activity:
***[[Ras|H-ras]]
***[[Ras|K-ras]], also determines patient [[prognosis]]
***[[Ras|N-ras]]
**[[Myc|C-myc]]
**C-raf
**[[Tumor suppressor gene|Tumor suppressor genes]] [[Retinoblastoma|retinoblastoma (Rb)]] and [[P53 (protein)|p53]]
**Mutations of [[APOBEC1|APOBEC protein]]
**Mutations of [[APOBEC1|APOBEC protein]]
==Genetics==
==Genetics==
* Genes involved in the pathogenesis of adenocarcinoma of the lung include:<ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref><ref name="pmid17625570">{{cite journal| author=Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al.| title=Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. | journal=Nature | year= 2007 | volume= 448 | issue= 7153 | pages= 561-6 | pmid=17625570 | doi=10.1038/nature05945 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17625570  }} </ref><ref name="pmid22919003">{{cite journal| author=Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM et al.| title=Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. | journal=Clin Cancer Res | year= 2012 | volume= 18 | issue= 17 | pages= 4570-9 | pmid=22919003 | doi=10.1158/1078-0432.CCR-12-0550 | pmc=PMC3703205 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22919003  }} </ref><ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref>  
 
** [[epidermal growth factor receptor|EGFR]] (7p11)  
==== Molecular pathogenesis of adenocarcinoma of the lung ====
** [[KRAS]] (12p12)  
* Somatic copy number alterations affect a large fraction of the cancer cell genome and are also associated with lung cancer.<ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref><ref name="pmid17625570">{{cite journal| author=Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al.| title=Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. | journal=Nature | year= 2007 | volume= 448 | issue= 7153 | pages= 561-6 | pmid=17625570 | doi=10.1038/nature05945 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17625570  }} </ref><ref name="pmid22919003">{{cite journal| author=Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM et al.| title=Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. | journal=Clin Cancer Res | year= 2012 | volume= 18 | issue= 17 | pages= 4570-9 | pmid=22919003 | doi=10.1158/1078-0432.CCR-12-0550 | pmc=PMC3703205 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22919003  }} </ref><ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref><ref name="WeirWoo2007">{{cite journal|last1=Weir|first1=Barbara A.|last2=Woo|first2=Michele S.|last3=Getz|first3=Gad|last4=Perner|first4=Sven|last5=Ding|first5=Li|last6=Beroukhim|first6=Rameen|last7=Lin|first7=William M.|last8=Province|first8=Michael A.|last9=Kraja|first9=Aldi|last10=Johnson|first10=Laura A.|last11=Shah|first11=Kinjal|last12=Sato|first12=Mitsuo|last13=Thomas|first13=Roman K.|last14=Barletta|first14=Justine A.|last15=Borecki|first15=Ingrid B.|last16=Broderick|first16=Stephen|last17=Chang|first17=Andrew C.|last18=Chiang|first18=Derek Y.|last19=Chirieac|first19=Lucian R.|last20=Cho|first20=Jeonghee|last21=Fujii|first21=Yoshitaka|last22=Gazdar|first22=Adi F.|last23=Giordano|first23=Thomas|last24=Greulich|first24=Heidi|last25=Hanna|first25=Megan|last26=Johnson|first26=Bruce E.|last27=Kris|first27=Mark G.|last28=Lash|first28=Alex|last29=Lin|first29=Ling|last30=Lindeman|first30=Neal|last31=Mardis|first31=Elaine R.|last32=McPherson|first32=John D.|last33=Minna|first33=John D.|last34=Morgan|first34=Margaret B.|last35=Nadel|first35=Mark|last36=Orringer|first36=Mark B.|last37=Osborne|first37=John R.|last38=Ozenberger|first38=Brad|last39=Ramos|first39=Alex H.|last40=Robinson|first40=James|last41=Roth|first41=Jack A.|last42=Rusch|first42=Valerie|last43=Sasaki|first43=Hidefumi|last44=Shepherd|first44=Frances|last45=Sougnez|first45=Carrie|last46=Spitz|first46=Margaret R.|last47=Tsao|first47=Ming-Sound|last48=Twomey|first48=David|last49=Verhaak|first49=Roel G. W.|last50=Weinstock|first50=George M.|last51=Wheeler|first51=David A.|last52=Winckler|first52=Wendy|last53=Yoshizawa|first53=Akihiko|last54=Yu|first54=Soyoung|last55=Zakowski|first55=Maureen F.|last56=Zhang|first56=Qunyuan|last57=Beer|first57=David G.|last58=Wistuba|first58=Ignacio I.|last59=Watson|first59=Mark A.|last60=Garraway|first60=Levi A.|last61=Ladanyi|first61=Marc|last62=Travis|first62=William D.|last63=Pao|first63=William|last64=Rubin|first64=Mark A.|last65=Gabriel|first65=Stacey B.|last66=Gibbs|first66=Richard A.|last67=Varmus|first67=Harold E.|last68=Wilson|first68=Richard K.|last69=Lander|first69=Eric S.|last70=Meyerson|first70=Matthew|title=Characterizing the cancer genome in lung adenocarcinoma|journal=Nature|volume=450|issue=7171|year=2007|pages=893–898|issn=0028-0836|doi=10.1038/nature06358}}</ref>
** [[BRAF]] (7q34)
**Copy-number gain of [[Chromosome 5|chromosome 5p]] has been identified as the most frequent alteration in lung adenocarcinoma followed by [[Chromosome 3 (human)|chromosome 3q]].
** [[PIK3CA]] (3q26)
**The [[KRAS|Kirsten rat sarcoma viral oncogene (''KRAS'')]] pathway is commonly found in smokers.<ref name="pmid3048648">{{cite journal |vauthors=Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC, Bos JL |title=Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung |journal=Cancer Res. |volume=48 |issue=20 |pages=5738–41 |date=October 1988 |pmid=3048648 |doi= |url=}}</ref>
** [[ERBB2IP|ERBB2]] (17q12)
**Mutation in [[EGFR|epidermal growth factor receptor (''EGFR'')]], particularly in-frame deletions are associated with never-smoking status, female gender, and East Asian ethnicity.<ref name="pmid22980975">{{cite journal |vauthors=Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M |title=Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing |journal=Cell |volume=150 |issue=6 |pages=1107–20 |date=September 2012 |pmid=22980975 |pmc=3557932 |doi=10.1016/j.cell.2012.08.029 |url=}}</ref>
** [[Chromosomal translocation|Translocation]] EML4/[[anaplastic lymphoma kinase|ALK]]  
**Focal amplifications of 14q13·3 are also frequent in adenocarcinoma of the lung, region coding for NKX2–1 [[TTF1 (gene)|(TTF1)]], a [[transcription factor]] crucial for development of the [[lung]], [[thyroid]], and [[brain]].
** [[Tyrosine kinase|Tyrosine kinase fusions]]  
**[[RBM10]] mutation is more prevalent in men.
** [[ALK(+)-ALCL|ALK]] (2p23), [[ROS1]] (6q22), and [[RET proto-oncogene|RET]] (10q11)
**Mutation in MGA, coding for a Max-interacting protein, which functions as a transcriptional repressor capable of blocking MYC-dependent transformation.<ref name="HurlinHuang2006">{{cite journal|last1=Hurlin|first1=Peter J.|last2=Huang|first2=Jie|title=The MAX-interacting transcription factor network|journal=Seminars in Cancer Biology|volume=16|issue=4|year=2006|pages=265–274|issn=1044579X|doi=10.1016/j.semcancer.2006.07.009}}</ref>
**Some of the other recurrent somatic copy number alterations in [[Adenocarcinoma of the lung|lung adenocarcinoma]] include:
***[[Amplification|Amplifications]] in MET, [[ERBB2IP|ERBB2]]'','' and [[MDM2]].
***[[Deletion (genetics)|Deletions]] in [[LRP1B]], [[PTPRD]]'','' and [[CDKN2A]].
***Fusion in [[ALK(+)-ALCL|ALK]]'','' [[ROS1]]'','' and [[RET gene|RET]].<ref name="pmid26149886">{{cite journal |vauthors=Devarakonda S, Morgensztern D, Govindan R |title=Genomic alterations in lung adenocarcinoma |journal=Lancet Oncol. |volume=16 |issue=7 |pages=e342–51 |date=July 2015 |pmid=26149886 |doi=10.1016/S1470-2045(15)00077-7 |url=}}</ref>
{| class="wikitable"
|Mutations
|''TP53, KRAS, EGFR, NF1, BRAF, MET, RIT''
|-
|Fusions
|''ALK, ROS1, RET''
|-
|SCNAs
|Gains: ''NKX2-1, TERT, EGFR, MET, KRAS, ERBB2, MDM2''
Losses: ''LRP1B, PTPRD, and CDKN2A''
|-
|Pathway alterations
|RTK/RAS/RAF
mTOR JAK-STAT DNA repair Cell cycle regulation Epigenetic deregulation
|}
 
==Gross Pathology==
==Gross Pathology==
* On gross pathology, peripheral multifocal [[Lesion|lesions]] are characteristic findings in [[Patient|patients]] with adenocarcinoma of the lung.<ref>Adenocarcinoma of the lung. Librepathology 2015. http://librepathology.org/wiki/index.php/File:Adenocarcinoma_%283950819000%29.jpg </ref>
* On gross pathology, peripheral multifocal [[Lesion|lesions]] are characteristic findings in [[Patient|patients]] with adenocarcinoma of the lung.<ref>Adenocarcinoma of the lung. Librepathology 2015. http://librepathology.org/wiki/index.php/File:Adenocarcinoma_%283950819000%29.jpg </ref>
* Adenocarcinoma of the lung may be preceded by [[Morphology (biology)|morphological]] changes such as atypical adenomatous hypertrophy (AAH) in peripheral [[Respiratory epithelium|airway cells]].
* AAH is a [[Parenchyma|parenchymal]] lesion that arises in the [[Pulmonary alveolus|alveoli]] close to [[Bronchiole|terminal and respiratory bronchioles]].
* AAH lesions are small and usually incidental [[Histology|histological findings]]; however, they may be detected [[Gross examination|grossly]], especially if they are 0.5 cm or larger.
* AAH is characterized by an alveolar structure lined by rounded, cuboidal, or low columnar cells.
* The postulated progression of AAH to adenocarcinoma with bronchioloalveolar features, apparent from the increasingly atypical morphology, is supported by morphometric, cyto-fluorometric, and molecular studies.
[[File:Lung_adenocarcinoma1.jpg|200px|center|thumb|Gray-tan tumor seen predominantly at the periphery. <br> Source: [https://librepathology.org/wiki/File:Acinar_pattern_adenocarcinoma_of_lung_--_intermed_mag.jpg Libre pathology]]]
[[File:Lung_adenocarcinoma1.jpg|200px|center|thumb|Gray-tan tumor seen predominantly at the periphery. <br> Source: [https://librepathology.org/wiki/File:Acinar_pattern_adenocarcinoma_of_lung_--_intermed_mag.jpg Libre pathology]]]
{|
{|
Line 40: Line 88:
[[File:Lung_adenocarcinoma3.jpg|200px|center|thumb|Micrograph showing an adenocarcinoma of the lung (acinar pattern), H&E stain. <br> Source: [https://librepathology.org/wiki/File:Acinar_pattern_adenocarcinoma_of_lung_--_intermed_mag.jpg Libre pathology]]]
[[File:Lung_adenocarcinoma3.jpg|200px|center|thumb|Micrograph showing an adenocarcinoma of the lung (acinar pattern), H&E stain. <br> Source: [https://librepathology.org/wiki/File:Acinar_pattern_adenocarcinoma_of_lung_--_intermed_mag.jpg Libre pathology]]]


 
<br>On microscopic [[Histopathology|histopathological]] analysis, nuclear atypia, eccentrically placed [[Cell nucleus|nuclei]], abundant [[cytoplasm]], and conspicuous [[Nucleolus|nucleoli]] are characteristic findings of adenocarcinoma of the lung.
<br>
*On microscopic [[Histopathology|histopathological]] analysis, nuclear atypia, eccentrically placed [[Cell nucleus|nuclei]], abundant [[cytoplasm]], and conspicuous [[Nucleolus|nucleoli]] are characteristic findings of adenocarcinoma of the lung.
*Atypical adenomatous hyperplasia (AAH): is the precursor of peripheral adenocarcinomas.  It consists of well demarcated [[Columnar epithelia|columnar]] or [[Cuboidal epithelia|cuboidal]] cells with the following features:<ref>{{cite book | last = Kumar | first = Vinay | title = Robbins basic pathology | publisher = Saunders/Elsevier | location = Philadelphia, PA | year = 2007 | isbn = 1416029737 }}</ref><ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref>
*Atypical adenomatous hyperplasia (AAH): is the precursor of peripheral adenocarcinomas.  It consists of well demarcated [[Columnar epithelia|columnar]] or [[Cuboidal epithelia|cuboidal]] cells with the following features:<ref>{{cite book | last = Kumar | first = Vinay | title = Robbins basic pathology | publisher = Saunders/Elsevier | location = Philadelphia, PA | year = 2007 | isbn = 1416029737 }}</ref><ref>{{cite book | last = Stewart | first = Bernard | title = World cancer report 2014 | publisher = International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization | location = Lyon, France Geneva, Switzerland | year = 2014 | isbn = 9283204298 }}</ref>
**Varying degrees of cytologic [[atypia]]  
**Varying degrees of cytologic [[atypia]]  

Revision as of 15:35, 26 February 2019

Adenocarcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adenocarcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Intervention

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adenocarcinoma of the lung pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adenocarcinoma of the lung pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adenocarcinoma of the lung pathophysiology

CDC on Adenocarcinoma of the lung pathophysiology

Adenocarcinoma of the lung pathophysiology in the news

Blogs on Adenocarcinoma of the lung pathophysiology

Directions to Hospitals Treating Adenocarcinoma of the lung

Risk calculators and risk factors for Adenocarcinoma of the lung pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2], Shanshan Cen, M.D. [3], Sudarshana Datta, MD [4]

Overview

Adenocarcinoma is the most common type of lung cancer found in non-smokers and is usually seen as a peripheral lesion in the lungs. In past several years many genetic and environmental factors has been identified as a causative factor for lung cancer. Individual susceptibility, active smoking, radon exposure, exposure to high pollution levels, asbestos exposure, occupational or environmental exposure to particular agents or carcinogens contribute to the development of adenocarcinoma of the lung. Hydrocarbons cause damage to the DNA and form DNA adducts. Benzo-A-pyrine has effects on inducing p53 mutations and affects molecular signaling pathways such as AKT. Genes involved in the pathogenesis of adenocarcinoma of the lung include EGFR, HER2, KRAS, ALK, and BRAF. On gross pathology, peripheral multifocal lesions are characteristic findings in patients with adenocarcinoma of the lung. On microscopic histopathological analysis, nuclear atypia, eccentrically placed nuclei, abundant cytoplasm, and conspicuous nucleoli are characteristic findings of adenocarcinoma of the lung.

Pathogenesis

Field of injury and field cancerization

Genetics

Molecular pathogenesis of adenocarcinoma of the lung

Mutations TP53, KRAS, EGFR, NF1, BRAF, MET, RIT
Fusions ALK, ROS1, RET
SCNAs Gains: NKX2-1, TERT, EGFR, MET, KRAS, ERBB2, MDM2

Losses: LRP1B, PTPRD, and CDKN2A

Pathway alterations RTK/RAS/RAF

mTOR JAK-STAT DNA repair Cell cycle regulation Epigenetic deregulation

Gross Pathology

  • On gross pathology, peripheral multifocal lesions are characteristic findings in patients with adenocarcinoma of the lung.[19]
  • Adenocarcinoma of the lung may be preceded by morphological changes such as atypical adenomatous hypertrophy (AAH) in peripheral airway cells.
  • AAH is a parenchymal lesion that arises in the alveoli close to terminal and respiratory bronchioles.
  • AAH lesions are small and usually incidental histological findings; however, they may be detected grossly, especially if they are 0.5 cm or larger.
  • AAH is characterized by an alveolar structure lined by rounded, cuboidal, or low columnar cells.
  • The postulated progression of AAH to adenocarcinoma with bronchioloalveolar features, apparent from the increasingly atypical morphology, is supported by morphometric, cyto-fluorometric, and molecular studies.
Gray-tan tumor seen predominantly at the periphery.
Source: Libre pathology

Microscopic Pathology

Micrograph of mucinous adenocarcinoma of the lung, H&E stain.
Source: Libre pathology
Micrograph showing an adenocarcinoma of the lung (acinar pattern), H&E stain.
Source: Libre pathology


On microscopic histopathological analysis, nuclear atypia, eccentrically placed nuclei, abundant cytoplasm, and conspicuous nucleoli are characteristic findings of adenocarcinoma of the lung.

  • Atypical adenomatous hyperplasia (AAH): is the precursor of peripheral adenocarcinomas. It consists of well demarcated columnar or cuboidal cells with the following features:[20][21]
  • As adenocarcinoma is a derivative of mucus producing glands in the lungs, it tends to stain mucin positive.
  • Based on differentiation, the tumor may be:
    • Well differentiated (low grade) : Normal appearance
    • Poorly differentiated (high grade): Abnormal glandular appearance with a positive mucin stain

Histological Subtypes

  • The IASLC/ATS/ERS lung adenocarcinoma histologic classification system was proposed in the Journal of Thoracic Oncology in 2011.[22]
  • According to this new classification, tumor size ≤3 cm with pure lepidic pattern, but without lymphatic, vascular, pleural invasion or tumor necrosis was defined as adenocarcinoma in situ (AIS).
  • If tumor size ≤3 cm with a lepidic predominant pattern and contained ≤5 mm stromal invasion it was defined as minimally invasive adenocarcinoma (MIA).
  • If tumor had >5 mm stromal invasion it was defined as an invasive adenocarcinoma.
  • Histologically adenocarcinoma is divided in to following subtypes:[23][24][25][26][27][28]
    • Lepidic adenocarcinoma
    • Acinar adenocarcinoma:
      • Acinar pattern comprises infiltrating round to oval glands lined by tumour cells.
      • Irregular-shaped glands.
      • Malignant cells: Hyperchromatic nuclei, fibroblastic stroma.
      • Sometimes the glandular cells and lumina may contain mucin.
    • Papillary adenocarcinoma
      • The papillary pattern is composed of glandular tumour cells growing along fibrovascular cores.
      • Papillae, necrosis, surrounding invasion, cuboidal to columnar epithelial lining, mucinous or non-mucinous.
      • Lung adenocarcinomas with papillary growth show 2 types of papillary architecture:
        • True papillary type: Papillae containing a layered glandular epithelium surrounded by fibrovascular core.
        • Micropapillary type: The papillary tufts lack a central fibrovascular core and extensively shed within alveolar spaces.
    • Micropapillary adenocarcinoma:
      • The papillary tufts lack a central fibrovascular core and extensively shed within alveolar spaces.
      • Micropapillary growth has been associated with an aggressive clinical course compared with traditional papillary adenocarcinoma.
      • Micropapillary adenocarcinoma (MPA) may be often diagnosed at a high stage in nonsmokers, with intralobar satellites.
      • Micropapillary adenocarcinoma frequently metastasizes to the contralateral lung, mediastinal lymph nodes, bone, and adrenal glands, with high mortality.
    • Solid adenocarcinoma
      • Cohesive cell cluster in a nest-like pattern without acinar polarity are the hallmark of the solid growth pattern.
      • Solid adenocarcinoma consists of sheets of tumor cells with abundant cytoplasm and mostly vesicular nuclei with several conspicuous nucleoli.
      • No acinar, papillary, or lepidic patterns are seen and there was no suggestion of mucin in tumor cell cytoplasm
    • Invasive mucinous adenocarcinoma
      • Mixed invasive mucinous: Invasive mucinous adenocarcinoma demonstrates areas with lepidic, acinar, and papillary patterns.
        • Fibrotic focus that contains invasive tumor with a desmoplastic stroma.
        • The tumor consists of columnar cells filled with abundant mucin in the apical cytoplasm and shows small, basally oriented nuclei.
      • Nonmucinous adenocarcinoma
    • Colloid adenocarcinoma:
      • This tumor consists of abundant pools of mucin growing within and distending airspaces.
      • Well differentiated mucinous glandular epithelium along the surface of fibrous septa and within the pools of mucin.
      • Tumor cells may be very inconspicuous.
      • The surface of the fibrous wall may be lined by well-differentiated cuboidal or columnar mucinous epithelium.
    • Fetal adenocarcinoma:
      • Fetal adenocarcinoma consists of malignant glandular cells growing in tubules and papillary structures with endometrioid morphology.
      • Some tumor cells have prominent clear cytoplasm, and squamoid morules are present
    • Enteric adenocarcinoma:
      • Consists of an adenocarcinoma that morphologically resembles colonic adenocarcinoma with back-to-back angulated acinar structures.
      • The tumor cells are cuboidal to columnar with nuclear pseudostratification.
      • The tumor stains strongly for CDX-2.
    • Minimally invasive adenocarcinoma (MIA)
      • Nonmucinous (MIA):
        • This subpleural adenocarcinoma tumor consists primarily of lepidic growth with a small (0.5 cm) central area of invasion.
        • It may present as the lepidic pattern and/or acinar invasion.
      • Mucinous (MIA):
        • Mucinous MIA consists of a tumor showing lepidic growth and a small (0.5 cm) area of invasion.
        • The tumor cells consist of mucinous columnar cells and pale cytoplasm resembling goblet cells growing mostly in a lepidic pattern along the surface of alveolar walls.
        • The tumor invades the areas of stromal fibrosis in an acinar pattern.
        • Low grade differentiation.
    • Preinvasive lesions
      • Atypical adenomatous hyperplasia (AAH): Consists of atypical pneumocytes proliferating along alveolar walls.
        • Non invasive.
        • The slightly atypical pneumocytes are cuboidal and show gaps between the cells.
        • Nuclei are hyperchromatic and may present with nuclear enlargement and multinucleation.
      • Adenocarcinoma in situ (AIS)
        • Nonmucinous (AIS): Tumor grows purely with a lepidic pattern.
          • No foci of invasion or scarring is seen.
          • It shows atypical pneumocytes proliferating along the thickened, but preserved, alveolar walls.
        • Mucinous AIS: Consists of a nodular proliferation of mucinous columnar cells growing in a purely lepidic pattern.
          • Although there is a small central scar, no stromal or vascular invasion is seen.
          • The tumor cells consist of cuboidal to columnar cells with abundant apical mucin and small, basally oriented nuclei.

References

  1. Travis WD, Travis LB, Devesa SS (January 1995). "Lung cancer". Cancer. 75 (1 Suppl): 191–202. doi:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID 8000996.
  2. Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. "Chapter 13, box on morphology of adenocarcinoma". Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN 1-4160-2973-7.
  3. Kanwal, Madiha; Ding, Xiao-Ji; Cao, Yi (2017). "Familial risk for lung cancer". Oncology Letters. 13 (2): 535–542. doi:10.3892/ol.2016.5518. ISSN 1792-1074.
  4. Kadara, H.; Scheet, P.; Wistuba, I. I.; Spira, A. E. (2016). "Early Events in the Molecular Pathogenesis of Lung Cancer". Cancer Prevention Research. 9 (7): 518–527. doi:10.1158/1940-6207.CAPR-15-0400. ISSN 1940-6207.
  5. Raso, Maria Gabriela; Wistuba, Ignacio I. (2007). "Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers". Journal of Thoracic Oncology. 2 (7): S128–S135. doi:10.1097/JTO.0b013e318074fe42. ISSN 1556-0864.
  6. Wistuba II, Gazdar AF (2006). "Lung cancer preneoplasia". Annu Rev Pathol. 1: 331–48. doi:10.1146/annurev.pathol.1.110304.100103. PMID 18039118.
  7. Devarakonda, Siddhartha; Morgensztern, Daniel; Govindan, Ramaswamy (2015). "Genomic alterations in lung adenocarcinoma". The Lancet Oncology. 16 (7): e342–e351. doi:10.1016/S1470-2045(15)00077-7. ISSN 1470-2045.
  8. Kadara H, Scheet P, Wistuba II, Spira AE (July 2016). "Early Events in the Molecular Pathogenesis of Lung Cancer". Cancer Prev Res (Phila). 9 (7): 518–27. doi:10.1158/1940-6207.CAPR-15-0400. PMID 27006378.
  9. Auerbach, Oscar; Stout, A. P.; Hammond, E. Cuyler; Garfinkel, Lawrence (1961). "Changes in Bronchial Epithelium in Relation to Cigarette Smoking and in Relation to Lung Cancer". New England Journal of Medicine. 265 (6): 253–267. doi:10.1056/NEJM196108102650601. ISSN 0028-4793.
  10. Stewart, Bernard (2014). World cancer report 2014. Lyon, France Geneva, Switzerland: International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization. ISBN 9283204298.
  11. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S; et al. (2007). "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer". Nature. 448 (7153): 561–6. doi:10.1038/nature05945. PMID 17625570.
  12. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM; et al. (2012). "Identifying and targeting ROS1 gene fusions in non-small cell lung cancer". Clin Cancer Res. 18 (17): 4570–9. doi:10.1158/1078-0432.CCR-12-0550. PMC 3703205. PMID 22919003.
  13. Stewart, Bernard (2014). World cancer report 2014. Lyon, France Geneva, Switzerland: International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization. ISBN 9283204298.
  14. Weir, Barbara A.; Woo, Michele S.; Getz, Gad; Perner, Sven; Ding, Li; Beroukhim, Rameen; Lin, William M.; Province, Michael A.; Kraja, Aldi; Johnson, Laura A.; Shah, Kinjal; Sato, Mitsuo; Thomas, Roman K.; Barletta, Justine A.; Borecki, Ingrid B.; Broderick, Stephen; Chang, Andrew C.; Chiang, Derek Y.; Chirieac, Lucian R.; Cho, Jeonghee; Fujii, Yoshitaka; Gazdar, Adi F.; Giordano, Thomas; Greulich, Heidi; Hanna, Megan; Johnson, Bruce E.; Kris, Mark G.; Lash, Alex; Lin, Ling; Lindeman, Neal; Mardis, Elaine R.; McPherson, John D.; Minna, John D.; Morgan, Margaret B.; Nadel, Mark; Orringer, Mark B.; Osborne, John R.; Ozenberger, Brad; Ramos, Alex H.; Robinson, James; Roth, Jack A.; Rusch, Valerie; Sasaki, Hidefumi; Shepherd, Frances; Sougnez, Carrie; Spitz, Margaret R.; Tsao, Ming-Sound; Twomey, David; Verhaak, Roel G. W.; Weinstock, George M.; Wheeler, David A.; Winckler, Wendy; Yoshizawa, Akihiko; Yu, Soyoung; Zakowski, Maureen F.; Zhang, Qunyuan; Beer, David G.; Wistuba, Ignacio I.; Watson, Mark A.; Garraway, Levi A.; Ladanyi, Marc; Travis, William D.; Pao, William; Rubin, Mark A.; Gabriel, Stacey B.; Gibbs, Richard A.; Varmus, Harold E.; Wilson, Richard K.; Lander, Eric S.; Meyerson, Matthew (2007). "Characterizing the cancer genome in lung adenocarcinoma". Nature. 450 (7171): 893–898. doi:10.1038/nature06358. ISSN 0028-0836.
  15. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC, Bos JL (October 1988). "Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung". Cancer Res. 48 (20): 5738–41. PMID 3048648.
  16. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M (September 2012). "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing". Cell. 150 (6): 1107–20. doi:10.1016/j.cell.2012.08.029. PMC 3557932. PMID 22980975.
  17. Hurlin, Peter J.; Huang, Jie (2006). "The MAX-interacting transcription factor network". Seminars in Cancer Biology. 16 (4): 265–274. doi:10.1016/j.semcancer.2006.07.009. ISSN 1044-579X.
  18. Devarakonda S, Morgensztern D, Govindan R (July 2015). "Genomic alterations in lung adenocarcinoma". Lancet Oncol. 16 (7): e342–51. doi:10.1016/S1470-2045(15)00077-7. PMID 26149886.
  19. Adenocarcinoma of the lung. Librepathology 2015. http://librepathology.org/wiki/index.php/File:Adenocarcinoma_%283950819000%29.jpg
  20. Kumar, Vinay (2007). Robbins basic pathology. Philadelphia, PA: Saunders/Elsevier. ISBN 1416029737.
  21. Stewart, Bernard (2014). World cancer report 2014. Lyon, France Geneva, Switzerland: International Agency for Research on Cancer,Distributed by WHO Press, World Health Organization. ISBN 9283204298.
  22. . doi:10.3978/j.issn.2072-1439.2014.09.13. Missing or empty |title= (help)
  23. Travis, William (2004). Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press. ISBN 9283224183.
  24. "www.jto.org".
  25. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Nakatani Y, Petersen I, Roggli V, Thunnissen E, Tsao M (May 2013). "Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification". Arch. Pathol. Lab. Med. 137 (5): 685–705. doi:10.5858/arpa.2012-0264-RA. PMID 22913371.
  26. Iwata H (September 2016). "Adenocarcinoma containing lepidic growth". J Thorac Dis. 8 (9): E1050–E1052. doi:10.21037/jtd.2016.08.78. PMID 27747060.
  27. Jones KD (December 2013). "Whence lepidic?: the history of a Canadian neologism". Arch. Pathol. Lab. Med. 137 (12): 1822–4. doi:10.5858/arpa.2013-0144-HP. PMID 23937575.
  28. Lin, Gengpeng; Xie, Canmao (2017). "PUB070 Acinar-Predominant Pattern Correlates with Poorer Outcome in Invasive Mucinous Adenocarcinoma of the Lung". Journal of Thoracic Oncology. 12 (1): S1489. doi:10.1016/j.jtho.2016.11.2040. ISSN 1556-0864.


Template:WikiDoc Sources